Quarterly loss narrows to $24.7M at Voyager Therapeutics (VYGR), while collaboration revenue falls.

Voyager Therapeutics (VYGR) reported a narrowed net loss of $24.7 million in Q3 2026, down from $27.9 million a year earlier, and a nine-month net loss of $77.1 million, also an improvement. However, collaboration revenue significantly decreased to $4.01 million for the quarter and $9.77 million for the first nine months. The company stated it has $132.1 million in cash, cash equivalents, and marketable securities, expected to fund operations for at least twelve months.